EPIToPe (Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs)-Feb 2018 to Jan 2023
An estimated 200,000 people in the UK have been infected with the Hepatitis C Virus (HCV), which is an important cause of liver disease, cancer and death. Most HCV infections in the UK are in people who inject drugs. New Direct Acting Antiviral (DAA) HCV therapies now combine high cure rates (>90%) with short treatment duration (8-12 weeks).
EPIToPe aims to generate empirical evidence on the effectiveness of HCV “Treatment as Prevention“in People who Inject Drugs (PWID). Despite effective prevention interventions, chronic HCV prevalence is still 40% among PWID. Evidence from mathematical modelling suggests that HCV treatment is essential to achieving substantial reductions in HCV prevalence and incidence among PWID. EPIToPE aims to test whether scaling up HCV DAA treatment will reduce chronic HCV prevalence and transmission among PWID.
Sharon Hutchinson (co-PI, Glasgow Caledonian University) , Matt Hickman (co-PI, University of Bristol), John Dillon (University of Dundee), Daniela De Angelis (MRC Biostatistics Unit, University of Cambridge), Lawrie Elliott (GCU), Graham Foster (Queen Mary, University of London), David Goldberg (GCU, Health Protection Scotland), Natasha Martin (UoB), Ann Eriksen (NHS Tayside), Peter Donnan (UoD), Sema Mandal (Public Health England), Peter Vickerman (UoB), William Hollingworth (UoB), David Liddell (Scottish Drugs Forum), Paul Flowers (GCU), Samreen Ijaz (PHE), Magdalena Harris (London School of Hygiene and Tropical Medicine) Contact: firstname.lastname@example.org.
Funded by the National Institute for Health Research (NIHR), Programme Grant for Applied Research (RP-PG-0616-20008) £2.8 million.